Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that discovers and develops medicines for serious infectious diseases and cancer by enhancing the immune system. The company focuses on developing therapies that improve the immune system's ability to overcome evasion tactics used by cancer cells and viruses. Vir Bio's clinical development pipeline includes investigational therapies for hepatitis delta virus (HDV) and multiple solid tumors. For hepatitis delta, the company has initiated its registrational ECLIPSE clinical program, which evaluates the combination of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD). This program consists of three ongoing randomized, controlled trials: ECLIPSE 1, ECLIPSE 2, and ECLIPSE 3. ECLIPSE 1 and ECLIPSE 3 have completed enrollment. Topline results for ECLIPSE 1 are anticipated in the fourth quarter of 2026, while topline results for ECLIPSE 2 and ECLIPSE 3 are expected in the first quarter of 2027.